Aurgalys Team
Selected Customers
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]

.:: Diaxonhit [ALEHT] ::.

Diaxonhit group resulted from the merger of Exonhit and Ingen Biosciences on December 14th, 2012. Diaxonhit merged with Eurobio, on May 2017, becoming one of the largest french company in the field of In Vitro Diagnostics (IVD) with a profroma turnover above €44M (S1-2017 figures). In septembre 2017, the group Diaxonhit completed the acquisition fo Genbio, its first in the US. For Diaxonhit, Genbio is a strategic acquisition, for its production capabilities, distribution networks in the US and Asia and its expertise in regulatory processes especially with the FDA. In addition, GenBio represents a backbone to attack the US market.

The coverage was initiated Feb 13th, 2013

Our target price for Diaxonhit as of March 9th, 2018, is €14.10/ share

From Nov 9th, 2017, Aurgalys analyst reports on Diaxonhit will be published in English and French

A partir du 9 novembre 2017, les rapports d’analyse d’Aurgalys sur Diaxonhit seront publiés en Français et en Anglais